All Videos

The panel addresses the role of allergy and immunology in CSU care and argues for a collaborative, access-focused approach between specialties.

The panel turns to treatment strategy—discussing appropriate antihistamine use, dose escalation, and when to move to advanced therapies.

In this episode titled "Shared Decision-Making and the Vitiligo Treatment Landscape," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD discuss the importance of individualized, goal-directed decision-making in vitiligo treatment and provide an overview of available therapeutic options.

Black Girl Sunscreen founder Shontay Lundy debunks SPF myths for skin of color, urging education, representation, and teamwork for healthier skin.

See how gene expression profiling bridges guideline gaps in high‑risk skin SCC, guiding radiation, follow‑up, and precision treatment decisions.

Konika Patel Schallen, MD, discussed new findings showing the Nordlys 1940 nm non-ablative fractional laser may reverse epigenetic markers of skin aging in a recent Dermatology Times interview.

Gene expression profiling refines cutaneous SCC risk beyond guidelines, influencing surveillance, radiation decisions, and neoadjuvant immunotherapy.

Roman Bronfenbrener, MD, discussed changing exit strategies, private equity, and why peer support may be one of the most valuable resources for independent dermatologists.

Philip J. Mease, MD, reviews guselkumab's mechanism of action and its expanded FDA-approved indication for psoriatic arthritis joint damage inhibition.

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed GX-03's encouraging interim safety profile, regulatory strategy, and next steps in clinical development.

Black Girl Sunscreen CEO and founder reveals why daily SPF matters for deeper skin tones, tackling white cast, education gaps, and inclusive sun care testing.

Christopher Bunick, MD, PhD, shared practical guidance on sun protection, swimming, and preserving the skin barrier in patients with atopic dermatitis.

Bradley Burnam, founder and CEO of Turn Therapeutics, explains the statistical rationale behind GX-03's phase 2 end point strategy and patient stratification.

Philip J. Mease, MD, explains the rationale for early biologic treatment in psoriatic arthritis following guselkumab's FDA label expansion to address structural joint damage.

Roman Bronfenbrener, MD, discussed how dermatologists are using AI to streamline documentation, summarize patient records, support clinical decision-making, and improve practice operations.

This episode, titled “Moving Beyond Long-Term Topical Corticosteroid Use in Inflammatory Dermatoses,” features panelists discussing the evolving role of topical corticosteroids in the management of chronic inflammatory skin diseases. Building on the consensus statement that topical corticosteroids should not be routinely prescribed for long-term use in chronic conditions, the expert faculty examine the distinction between acute flare management and long-term disease control.

In “Reducing Treatment Burden in Inflammatory Dermatoses,” our panel explores the practical challenges associated with managing chronic inflammatory skin diseases using multiple topical corticosteroids. Building on the consensus statement that the use of different corticosteroids for different body areas can create significant burden for patients, the expert faculty discuss how increasingly complex treatment regimens can negatively impact adherence, disease control, and the overall patient experience.

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed interim phase 2 trial findings showing GX-03 efficacy across a broader range of EASI severity scores in atopic dermatitis.

The panel explores how to differentiate CSU from chronic inducible urticaria and acute urticaria, including the potential for overlap between subtypes.

In this episode titled "Active vs. Stable Vitiligo: Defining Disease Activity and Psychosocial Burden," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD address the clinical distinction between active and stable vitiligo, as well as the significant psychological impact of the disease.

The panel examines how to distinguish CSU from other urticaria subtypes, how to approach angioedema, and how limited—or expansive—the diagnostic workup should be.

In this episode titled "Vitiligo Pathogenesis: How the JAK-STAT Pathway Drives Melanocyte Destruction," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD explore the immunological underpinnings of vitiligo and how this understanding has revolutionized treatment thinking.

Philip Mease, MD, reviews the APEX trial data supporting guselkumab's expanded FDA label for inhibition of structural joint damage in psoriatic arthritis.

LEADderm, led by Jennifer Soung, MD, helps dermatologists build leadership, AI readiness, and purpose-driven careers—leaving attendees energized, connected, and patient-focused.

Explore cutaneous SCC care from topical therapies and Mohs to adjuvant radiation and PD-1 immunotherapy, guided by shared decisions and profiling.

Learn how cutaneous SCC care shifts from topical therapy to Mohs, radiation, and PD-1 immunotherapy, guided by shared decisions and profiling.

Linda Stein Gold, MD, discusses zasocitinib's safety and efficacy as an oral treatment for plaque psoriasis.

Roman Bronfenbrener, MD, discusses how AI-generated patient diagnoses are reshaping dermatology visits and creating new challenges.

Kord Honda, MD, provides his first-line and adjunct treatment strategies for acne in recognition of Acne Awareness Month.

Linda Stein Gold, MD, reviews the recent LATITUDE Atlas head-to-head trial results showing zasocitinib's superiority over deucravacitinib for plaque psoriasis.